CLINUVEL PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.57 AUD | -2.80% |
|
+1.32% | -8.94% |
| 14/03 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
| 14/03 | Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16 | MT |
| Sales 2024 * | 89.47M 58.44M 4.87B | Sales 2025 * | 98.61M 64.41M 5.37B | Capitalization | 730M 477M 39.76B |
|---|---|---|---|---|---|
| Net income 2024 * | 34M 22.21M 1.85B | Net income 2025 * | 37M 24.17M 2.02B | EV / Sales 2024 * | 6.07 x |
| Net cash position 2024 * | 187M 122M 10.17B | Net cash position 2025 * | 219M 143M 11.95B | EV / Sales 2025 * | 5.18 x |
| P/E ratio 2024 * |
21.3
x | P/E ratio 2025 * |
19.7
x | Employees | - |
| Yield 2024 * |
0.46% | Yield 2025 * |
0.51% | Free-Float | 79.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Clinuvel Pharmaceuticals Limited
More press releases
More news
| 1 day | -2.80% | ||
| 1 week | +1.32% | ||
| Current month | +1.46% | ||
| 1 month | +5.96% | ||
| 3 months | -6.90% | ||
| 6 months | -4.96% | ||
| Current year | -8.94% |
1 week
14.11
15.40
1 month
14.0316.43
Current year
12.9617.20
1 year
12.9621.53
3 years
12.9644.67
5 years
12.9245.88
10 years
1.3045.88
| Managers | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 01/05/01 |
Darren M. Keamy
DFI | Director of Finance/CFO | - | 01/05/01 |
Lachlan Hay
COO | Chief Operating Officer | - | 01/07/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 01/05/01 |
| Director/Board Member | - | 06/07/06 | |
Karen Agersborg
BRD | Director/Board Member | - | 29/18/29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 14.57 | -2.80% | 54,613 |
| 24/24/24 | 14.99 | +0.67% | 106,329 |
| 23/24/23 | 14.89 | +4.49% | 75,814 |
| 22/24/22 | 14.25 | -0.90% | 122,966 |
| 19/24/19 | 14.38 | -5.95% | 254,065 |
Delayed Quote Australian S.E., April 26, 2024 at 11:40 am IST
More quotes
Clinuvel Pharmaceuticals Limited is a global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. The Company is engaged in managing and expanding commercial distribution of its lead drug candidate, SCENESSE, in Europe, the United States, Israel, and Australia for the treatment of a rare, genetic metabolic disorder, erythropoietic protoporphyria (EPP). The Companyâs pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural a-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.
Sector
Pharmaceuticals
Calendar
28/08/2024
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
14.57
AUD
Average target price
25.6
AUD
Spread / Average Target
+75.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.94% | 476M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- CUV Stock
